Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases.
The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes.
It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions.
In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease.
Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease.
The company was founded in 2015 and is headquartered in San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 9, 23 | -0.15 Increased by +68.75% | -0.19 Increased by +21.05% |
| Aug 9, 23 | -0.24 Increased by +42.86% | -0.31 Increased by +22.58% |
| May 11, 23 | -0.39 Increased by +4.88% | -0.74 Increased by +47.30% |
| Mar 30, 23 | -0.37 Increased by +47.89% | -0.51 Increased by +27.45% |
| Nov 14, 22 | -0.48 Decreased by -1.50 K% | -0.48 |
| Aug 11, 22 | -0.42 Increased by +75.72% | -0.45 Increased by +6.67% |
| May 13, 22 | -0.41 Decreased by -4.00 K% | -0.38 Decreased by -7.89% |
| Mar 28, 22 | -0.71 Increased by +35.59% | -0.46 Decreased by -54.35% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -5.86 M Increased by +48.60% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -7.59 M Increased by +23.56% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -9.36 M Increased by +6.23% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by -100.00% | -8.77 M Increased by +36.92% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -11.40 M Decreased by -4.67 K% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -9.93 M Decreased by -14.77% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -9.98 M Decreased by -87.22% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 284.00 K Increased by +N/A% | -13.89 M Decreased by N/A% | Decreased by -4.89 K% - |